提示: 手机请竖屏浏览!

劳拉替尼治疗一名ALK融合阳性高级别胶质瘤患儿
Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma


肿瘤 妇产科和儿科 • 2021.08.19
相关阅读
• 儿童高级别胶质瘤的溶瘤HSV-1 G207免疫病毒疗法 • 重组脊髓灰质炎病毒治疗复发性胶质母细胞瘤

致编辑:

分子诊断学的进展帮助我们发现了一类新的儿童胶质瘤——婴儿大脑半球胶质瘤,此类肿瘤起源于大脑半球,通常通过组织学检查确认为恶性(世界卫生组织Ⅲ级或Ⅳ级)1,2。这些胶质瘤在ALKROS1NTRK1/2/3MET发生受体酪氨酸激酶重排;与儿童的其他高级别胶质瘤相比,此类肿瘤更易于治疗,生存结局也更好1,2

虽然生存结局优于其他胶质瘤,但婴儿大脑半球胶质瘤的治疗仍具有挑战性。这些胶质瘤的临床表现是发育中的大脑出现非常大的血管肿瘤,因此神经外科手术、化疗和放疗的联合应用常导致神经认知延迟、神经内分泌功能缺陷和寿命缩短2,3





作者信息

 

参考文献

1. Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10:4343-4343.

2. Clarke M, Mackay A, Ismer B, et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10:942-963.

3. El-Ayadi M, Ansari M, Sturm D, et al. High-grade glioma in very young children: a rare and particular patient population. Oncotarget 2017;8:64564-64578.

4. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:2018-2029.

5. Goldsmith KC, Kayser K, Groshen SG, et al. Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: a New Approaches to Neuroblastoma Consortium study. J Clin Oncol 2020;38(15):Suppl:10504-10504. abstract.

服务条款 | 隐私政策 | 联系我们